Power of two : combination of therapeutic approaches involving glucose transporter (GLUT) inhibitors to combat cancer
Copyright © 2020 Elsevier B.V. All rights reserved..
Cancer research of the Warburg effect, a hallmark metabolic alteration in tumors, focused attention on glucose metabolism whose targeting uncovered several agents with promising anticancer effects at the preclinical level. These agents' monotherapy points to their potential as adjuvant combination therapy to existing standard chemotherapy in human trials. Accordingly, several studies on combining glucose transporter (GLUT) inhibitors with chemotherapeutic agents, such as doxorubicin, paclitaxel, and cytarabine, showed synergistic or additive anticancer effects, reduced chemo-, radio-, and immuno-resistance, and reduced toxicity due to lowering the therapeutic doses required for desired chemotherapeutic effects, as compared with monotherapy. The combinations have been specifically effective in treating cancer glycolytic phenotypes, such as pancreatic and breast cancers. Even combining GLUT inhibitors with other glycolytic inhibitors and energy restriction mimetics seems worthwhile. Though combination clinical trials are in the early phase, initial results are intriguing. The various types of GLUTs, their role in cancer progression, GLUT inhibitors, and their anticancer mechanism of action have been reviewed several times. However, utilizing GLUT inhibitors as combination therapeutics has received little attention. We consider GLUT inhibitors agents that directly affect glucose transporters by binding to them or indirectly alter glucose transport by changing the transporters' expression level. This review mainly focuses on summarizing the effects of various combinations of GLUT inhibitors with other anticancer agents and providing a perspective on the current status.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:1874 |
---|---|
Enthalten in: |
Biochimica et biophysica acta. Reviews on cancer - 1874(2020), 2 vom: 20. Dez., Seite 188457 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Tilekar, Kalpana [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 18.01.2021 Date Revised 12.11.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.bbcan.2020.188457 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM316650234 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM316650234 | ||
003 | DE-627 | ||
005 | 20231225161540.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.bbcan.2020.188457 |2 doi | |
028 | 5 | 2 | |a pubmed24n1055.xml |
035 | |a (DE-627)NLM316650234 | ||
035 | |a (NLM)33096154 | ||
035 | |a (PII)S0304-419X(20)30176-1 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Tilekar, Kalpana |e verfasserin |4 aut | |
245 | 1 | 0 | |a Power of two |b combination of therapeutic approaches involving glucose transporter (GLUT) inhibitors to combat cancer |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 18.01.2021 | ||
500 | |a Date Revised 12.11.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2020 Elsevier B.V. All rights reserved. | ||
520 | |a Cancer research of the Warburg effect, a hallmark metabolic alteration in tumors, focused attention on glucose metabolism whose targeting uncovered several agents with promising anticancer effects at the preclinical level. These agents' monotherapy points to their potential as adjuvant combination therapy to existing standard chemotherapy in human trials. Accordingly, several studies on combining glucose transporter (GLUT) inhibitors with chemotherapeutic agents, such as doxorubicin, paclitaxel, and cytarabine, showed synergistic or additive anticancer effects, reduced chemo-, radio-, and immuno-resistance, and reduced toxicity due to lowering the therapeutic doses required for desired chemotherapeutic effects, as compared with monotherapy. The combinations have been specifically effective in treating cancer glycolytic phenotypes, such as pancreatic and breast cancers. Even combining GLUT inhibitors with other glycolytic inhibitors and energy restriction mimetics seems worthwhile. Though combination clinical trials are in the early phase, initial results are intriguing. The various types of GLUTs, their role in cancer progression, GLUT inhibitors, and their anticancer mechanism of action have been reviewed several times. However, utilizing GLUT inhibitors as combination therapeutics has received little attention. We consider GLUT inhibitors agents that directly affect glucose transporters by binding to them or indirectly alter glucose transport by changing the transporters' expression level. This review mainly focuses on summarizing the effects of various combinations of GLUT inhibitors with other anticancer agents and providing a perspective on the current status | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, N.I.H., Extramural | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Review | |
650 | 4 | |a Cancer | |
650 | 4 | |a Combination strategy | |
650 | 4 | |a Drug synergy | |
650 | 4 | |a GLUT inhibitors | |
650 | 4 | |a Glucose transporters (GLUTs) | |
650 | 7 | |a Antineoplastic Agents |2 NLM | |
650 | 7 | |a Glucose Transport Proteins, Facilitative |2 NLM | |
700 | 1 | |a Upadhyay, Neha |e verfasserin |4 aut | |
700 | 1 | |a Iancu, Cristina V |e verfasserin |4 aut | |
700 | 1 | |a Pokrovsky, Vadim |e verfasserin |4 aut | |
700 | 1 | |a Choe, Jun-Yong |e verfasserin |4 aut | |
700 | 1 | |a Ramaa, C S |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Biochimica et biophysica acta. Reviews on cancer |d 1998 |g 1874(2020), 2 vom: 20. Dez., Seite 188457 |w (DE-627)NLM097444006 |x 1879-2561 |7 nnns |
773 | 1 | 8 | |g volume:1874 |g year:2020 |g number:2 |g day:20 |g month:12 |g pages:188457 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bbcan.2020.188457 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 1874 |j 2020 |e 2 |b 20 |c 12 |h 188457 |